相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Ahmad I. Antar et al.
LEUKEMIA (2020)
A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia
Andreas Sellmer et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
Theodore C. Tarver et al.
BLOOD ADVANCES (2020)
Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases
Joseph Cioccio et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia
Xue Yuan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Availability of FLT3 inhibitors: how do we use them?
Alexander E. Perl
BLOOD (2019)
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies
Ellen Weisberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β-catenin, MYC, and WT1
Mandy Beyer et al.
CANCERS (2019)
Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases
Ferenc Baska et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
Nicholas J. Short et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells
Miriam Pons et al.
ARCHIVES OF TOXICOLOGY (2018)
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML
Jorge E. Cortes et al.
BLOOD (2018)
RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia
S. Rudat et al.
LEUKEMIA (2018)
HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130
Anja Goeder et al.
NATURE COMMUNICATIONS (2018)
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
Lauren Y. Lee et al.
BLOOD (2017)
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia
Ines Peschel et al.
HAEMATOLOGICA (2017)
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori et al.
INVESTIGATIONAL NEW DRUGS (2017)
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia
Marlise R. Luskin et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
Kerstin Maria Kampa-Schittenhelm et al.
ONCOTARGET (2017)
FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia
Ines Peschel et al.
HAEMATOLOGICA (2017)
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies
J. Kyle Bruner et al.
CANCER RESEARCH (2017)
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Catherine C. Smith et al.
BLOOD (2017)
Leukemogenic potency of the novel FLT3-N676K mutant
Kezhi Huang et al.
ANNALS OF HEMATOLOGY (2016)
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
Fangli Chen et al.
ONCOTARGET (2016)
FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia
Rohit A. Chougule et al.
ONCOTARGET (2016)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Cross talk of tyrosine kinases with the DNA damage signaling pathways
Kiran Mahajan et al.
NUCLEIC ACIDS RESEARCH (2015)
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 Gatekeeper F691L Mutation with PLX3397
Catherine C. Smith et al.
CANCER DISCOVERY (2015)
Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
Yi-Yu Ke et al.
SCIENTIFIC REPORTS (2015)
Inhibition of c-Kit by tyrosine kinase inhibitors
Allison Galanis et al.
HAEMATOLOGICA (2015)
PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph plus ) leukemias harboring the T315I mutation
A. A. Mian et al.
LEUKEMIA (2015)
Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
Julie A. Zorn et al.
PLOS ONE (2015)
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
Allison Galanis et al.
BLOOD (2014)
TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo
Hayley Ma et al.
BLOOD (2014)
G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia
Hee Kyu Lee et al.
BLOOD (2014)
SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia
Daniel Sasca et al.
BLOOD (2014)
FLT3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia
Hayley S. Ma et al.
CANCER RESEARCH (2014)
Crenolanib is a selective type I pan-FLT3 inhibitor
Catherine Choy Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia
Sabrina Opatz et al.
BLOOD (2013)
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
Eric I. Zimmerman et al.
BLOOD (2013)
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors
A. B. Williams et al.
LEUKEMIA (2013)
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
C. Albers et al.
LEUKEMIA (2013)
C-Kit controls IL-1β-induced effector functions in HMC-cells
Sebastian Drube et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220
Daphnie Pauwels et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Breakdown of the FLT3-ITD/STAT5 Axis and Synergistic Apoptosis Induction by the Histone Deacetylase Inhibitor Panobinostat and FLT3-Specific Inhibitors
Kristin Pietschmann et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
A. S. Moore et al.
LEUKEMIA (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality
Dirk Schmidt-Arras et al.
BLOOD (2009)
Bis(1H-indol-2-yl) methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro
Florian Heidel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
Nikolas von Bubnoff et al.
CANCER RESEARCH (2009)
Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor
Qi Chao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes
Chunaram Choudhary et al.
MOLECULAR CELL (2009)
Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms
A. Satyanarayana et al.
ONCOGENE (2009)
KIT regulates tyrosine phosphorylation and nuclear localization of β-catenin in mast cell leukemia
Tomohiro Kajiguchi et al.
LEUKEMIA RESEARCH (2008)
Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis
O. H. Kraemer et al.
ONCOGENE (2008)
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
Lisheng Wang et al.
BLOOD (2007)
FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells
Li Li et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412
C. H. Seedhouse et al.
LEUKEMIA (2006)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
F Heidel et al.
BLOOD (2006)
Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myelold transformation
CH Brandts et al.
CANCER RESEARCH (2005)
FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)
K Bagrintseva et al.
BLOOD (2005)
Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia
J Cools et al.
CANCER RESEARCH (2004)
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase
CD Mol et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
FLT3 mutations in acute myeloid leukemia cell lines
H Quentmeier et al.
LEUKEMIA (2003)
分享论文
